Reviewing recent guideline updates on the risk stratification and treatment of AML

In this episode of the VJHemOnc Podcast, we are joined by Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, and Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, to discuss recent guideline updates on the risk stratification and treatment of acute myeloid leukemia (AML). The experts discuss differences in the World Health Organization (WHO) and International Consensus Classification (ICC) definitions, the recent European Leukemia Network (ELN) updates to risk stratification, incorporating measurable residual disease (MRD) into therapeutic decision-making, and biomarkers or stratification approaches on the horizon.